

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
INC. and AKORN INC.,¹
Petitioners,

v.

ALLERGAN, INC.,
Patent Owner.

Case IPR2016-01127 (US 8,685,930 B2)
Case IPR2016-01128 (US 8,629,111 B2)
Case IPR2016-01129 (US 8,642,556 B2)
Case IPR2016-01130 (US 8,633,162 B2)
Case IPR2016-01131 (US 8,648,048 B2)
Case IPR2016-01132 (US 9,248,191 B2)

**PETITIONERS' REQUEST FOR ORAL ARGUMENT PURSUANT
TO 37 C.F.R. § 42.70**

¹ Cases IPR2017-00576 and IPR2017-00594, IPR2017-00578 and IPR2017-00596, IPR2017-00579 and IPR2017-00598, IPR2017-00583 and IPR2017-00599, IPR2017-00585 and IPR2017-00600, and IPR2017-00586 and IPR2017-00601, have respectively been joined with the captioned proceedings. The word-for-word identical paper is filed in each proceeding identified in the caption pursuant to the Board's Scheduling Order (Paper 10).

Pursuant to 37 C.F.R. § 42.70(a), Petitioners Mylan Pharmaceuticals Inc., Teva Pharmaceuticals USA, Inc., and Akorn Inc. hereby provide this Request for Oral Argument regarding the unpatentability of the involved claims of U.S. Patent Nos. 8,685,930; 8,629,111; 8642,556; 8633,162; 8648,048; and 9,248,191 on the instituted grounds and on any pending motions.

Petitioners requests no more than 90 minutes per side of oral argument. The Oral Argument will be held August 17, 2017, pursuant to the Scheduling Order (Paper 10).

Respectfully submitted,

Date: July 20, 2017

/ Steven W. Parmelee /

Steven W. Parmelee

Reg. No. 31,990

CERTIFICATE OF SERVICE

This is to certify that I caused to be served a true and correct copy of the foregoing Petitioners' Request for Oral Argument Pursuant to 37 C.F.R. § 42.70 on this 20th day of July, 2017, on the Patent Owner at the correspondence address of the Patent Owner as follows:

Dorothy P. Whelan
Michael Kane
Susan Morrison Colletti
Robert M. Oakes
Jonathan Singer
Fish & Richardson P.C.
3200 RBC Plaza
60 South Sixth Street
Minneapolis, MN 55402
Email: IPR13351-0008IP1@fr.com
Email: IPR13351-0008IP2@fr.com
Email: IPR13351-0008IP3@fr.com
Email: IPR13351-0008IP4@fr.com
Email: IPR13351-0008IP5@fr.com
Email: IPR13351-0008IP6@fr.com
Email: PTABInbound@fr.com

And on the remaining petitioners as follows:

Gary Speier
Mark Schuman
CARLSON, CASPERS, VANDENBURGH,
LINDQUIST & SCHUMAN, P.A.
225 South Sixth Street, Suite 4200
Minneapolis, MN 55402
Email: gspeier@carlsoncaspers.com
Email: mschuman@carlsoncaspers.com
Attorneys for Teva Pharmaceuticals USA, Inc.

Michael Dzwonczyk
Azadeh Kokabi
Travis Ribar
SUGHRUE MION, PLLC
2100 Pennsylvania Ave., NW
Washington, DC 20037
Email: mdzwonczyk@sughrue.com
Email: akokabi@sughrue.com
Email: tribar@sughrue.com
Attorneys for Akorn Inc.

Respectfully submitted,

Dated: July 20, 2017

/ Steven W. Parmelee /
Steven W. Parmelee, Lead Counsel
Reg. No. 31,990